Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive loss of multiple cognitive functions. Accumulation of amyloid beta oligomers (oAβ) play a major role in the neurotoxicity associated with the disease process. One of the early affected brain regions is the hippocampus, wherein a reduction of the vacuolar protein sorting-associated protein 35 (VPS35), the core protein comprising the retromer complex involved in cellular cargo sorting, has been identified. To investigate the role of the retromer function on the accumulation and clearance of oAβ, we reduced retromer function by selectively inhibiting VPS35 gene expression using siRNA in differentiated neuronal SH-SY5Y cells. As cell-to-cell transfer of oAβ to new brain regions is believed to be important for disease progression we investigated the effect of VPS35 reduction both in cells with direct uptake of oAβ and in cells receiving oAβ from donor cells. We demonstrate that reduced retromer function increases oAβ accumulation in both cell systems, both the number of cells containing intracellular oAβ and the amount within them. This effect was shown at different time points and regardless if the oAβ originated from the extracellular milieu or via a direct neuronal cell-to-cell transfer. Interestingly, not only did reduced VPS35 cause oAβ accumulation, but oAβ treatment alone also lead to a reduction of VPS35 protein content. The accumulated oAβ seems to co-localize with VPS35 and early endosome markers. Together, these findings provide evidence that reduced retromer function decreases the ability for neurons to transport and clear neurotoxic oAβ received through different routes resulting in the accumulation of oAβ. Thus, enhancing retromer function may be a potential therapeutic strategy to slow down the pathophysiology associated with the progression of AD.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive loss of multiple cognitive functions. The postmortem AD brain is characterized primarily by the depositions of amyloid plaques and neurofibrillary tangles, hallmark protein deposits composed primarily of cleaved amyloid beta (Aβ) fragments and hyperphosphorylated forms of the microtubule associated protein tau, respectively. While the exact aetiology responsible for the accumulation and toxicity of these hallmark protein inclusions remains relatively unknown, current converging evidence suggest that soluble oligomeric forms of Aβ (oAβ), rather than the insoluble amyloid plaques, are in part, responsible for the neurotoxic effects shown in the progression of the AD process (Freir et al., 2011; Lei et al., 2016; Li et al., 2011; Nagy et al., 1995; Nagy et al., 1996; Shankar et al., 2008) . These findings are consistent with the identification of oAβ assemblies in the brain and cerebrospinal fluid (CSF) of AD cases but not in aged-matched controls, suggesting a correlation between oAβ and cognitive decline (Herskovits et al., 2013; Kayed et al., 2003; McLean et al., 1999; Steinerman et al., 2008) . This has shifted the focus from the large extracellular Aβ plaques to oligomeric, intracellular Aβ assemblies. Accordingly, intraneuronal Aβ accumulation is observed prior to amyloid plaque formation within brain regions first affected by AD, being a pathological phenomenon that appears to be among the earliest changes in AD (Gouras et al., T 2000) . Moreover, the accumulation of Aβ in vulnerable distal neurites and synapses has also been linked to synapse failure, even prior to the development of amyloid plaques (Casas et al., 2004; Oddo et al., 2003; Takahashi et al., 2004; Takahashi et al., 2002) . These findings point to a pathological effect of intraneuronal Aβ accumulation (Glabe, 2001; Gouras et al., 2005) . In line with these findings, prion-like seeding of intracellular Aβ was recently confirmed (Olsson et al., 2018) . Thus, the plaques themselves are less likely to be directly toxic (Shankar et al., 2008) although the release of oAβ through the dynamic instability of the plaques is likely to be important for the pathophysiological process during AD progression, resulting in increased availability of toxic oligomers to surrounding synapses and cells (Hong et al., 2014) . The accumulation of intracellular oAβ within the cells and its associated toxicity also promotes the increase in cell-to-cell spread (Domert et al., 2014; Nath et al., 2012; Stopschinski and Diamond, 2017) . Different transfer mechanisms have been suggested to play a role in this process (Dunning et al., 2012) . We have previously showed that oAβ efficiently transfers from neuron to neuron, involving the endosomal and exosomal pathways, affecting the cell viability of the recipient cell confirming the neurotoxicity of oAβ (Domert et al., 2014; Nath et al., 2012; Sinha et al., 2018) The retromer system is a multi-protein complex system containing several vacuolar proteins (VPS) which include; VPS5, VPS17, VPS26, VPS29 and VPS35 and their associated family of VPS10 domain-containing receptors, including the sortilin-related receptor 1 (SORLA) (Arighi et al., 2004; Feinstein et al., 2011; Seaman, 2004; Temkin et al., 2011) . The retromer system is involved in intracellular cargo sorting and recycling, managing the two major transport routes out of the endosome. The first is the retrieval of cargos from endosomes and their delivery to the trans-Golgi network, and the second is responsible for the recycling of cargos from endosomes back to the cell surface (Arighi et al., 2004; Feinstein et al., 2011; Seaman, 2004; Temkin et al., 2011) . In late-onset post-mortem AD brains, molecular profiling of the hippocampal region identified a significant spatiotemporal RNA and protein reduction of VPS35 and the related VPS26 (Small et al., 2005) . Both cell culture studies (Small et al., 2005) and animal models (Muhammad et al., 2008) have shown that downregulation of VPS35 through selective silencing or secondary to VPS26 silencing, reduces the retromer function and increase the levels of Aβ peptides. Similarly, in Parkinson's disease (PD), dominant negative mutations within the VPS35 gene have been identified to cause a reduction in protein sorting and receptor recycling (Follett et al., 2017; Vilarino-Guell et al., 2011; Zimprich et al., 2011) . In fact, a direct link between retromer dysfunction and late onset PD has been suggested (Dhungel et al., 2015; Miura et al., 2014; Zavodszky et al., 2014) . Collectively, these studies indicate that the retromer complex is a key player in the pathophysiology of those neurodegenerative disorders that are characterized by hallmark protein aggregates. However, the direct link between reduced retromer function and oAβ accumulation in a propagation model of AD remains to be fully elucidated.
To elucidate the pathophysiological role of the retromer system in AD, we investigated its role in the accumulation and recycling of oAβ assemblies, either those absorbed from the extracellular milieu or those transferred from other neurons in a co-culture system. Retromer function was reduced in a cellular model system by inhibiting the expression of VPS35 using highly specific small interfering RNA (siRNA) sequences. Using this model, we demonstrate that reduced retromer function results in increased cellular accumulation of oAβ, either derived from the extracellular milieu or via neuron-to-neuron transfer. By monitoring the inclusion intensity of labelled oAβ by flow cytometry, we demonstrate that reduced retromer function increases the propensity of oAβ to accumulate within the cell. Furthermore, we demonstrate that oAβ treatment alone reduces VPS35 protein expression in control cells, directly linking oAβ and VPS35 reduction in AD. The accumulated oAβ seems to co-localize with VPS35 and early endosome markers. Collectively, our results corroborate VPS35, the core of the retromer complex, as a critical player involved in the proper recycling of exogenous oAβ assemblies associated with propagation of AD pathophysiology.
Materials and methods

Cell culture and differentiation
Human neuroblastoma SH-SY5Y cells (ECACC; Sigma Aldrich) were cultured in complete media containing MEM-GlutaMAX™ supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 50 U/ml penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine (all from Lonza) in 37°C with 5% CO 2 . Where noted, cells were differentiated with retinoic acid (RA) for 7 days (donor cells) or fully differentiated by seeding RA treated cells onto 20% Matrigel® matrix (Corning) differentiated in serum free MEM-GlutaMAX media supplemented with brain-derived neurotrophic factor (BDNF, 50 ng/ml, PeproTech), neuregulin β1 (NRGβ1, 10 ng/ml, R&D Systems), nerve growth factor (NGF, 10 ng/ml, R&D Systems) and vitamin D3 (VitD 3 , 24 nM, SigmaAldrich) for 10 days (recipient cells).
Oligomerization and labelling of Aβ1-42
Aβ1-42 was oligomerized and labelled with Alexa Fluor 700 (AF700) as previously described (Domert et al., 2014; Sinha et al., 2018) . Briefly, recombinant Aβ1-42 peptides (Innovagen,) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Sigma-Aldrich) and vacuum dried. Aβ1-42 (1.054 mM final concentration) was resuspended in Na 2 CO 3 (0.1 M pH 8.5) and incubated with the fluorophore Alexa Fluor 700 (AF700) succinimidyl ester (1.58 mM final concentration, Life Technologies). Labelled Aβ1-42 was diluted to a final concentration of 100 μM in HEPES 20 mM pH 7.4. After overnight incubation (4°C), oAβ1-42 was separated from monomers and free dye with size exclusion chromatography (SEC). oAβ-AF700 were resuspended and quantified spectrophotometrically at 215 nm and stored at −80°C.
VPS35 siRNA transfection
Donor or recipient cells were transfected with VPS35 siRNA (20 nM, Qiagen) using HiPerFect transfection reagent (Qiagen) in 100% Opti-MEM™ (Thermo Fisher Scientific) for 6 h at 37°C. As a control, cells were transfected with scrambled siRNA, a non-targeting siRNA with no homology to any known human gene (AllStars Negative Control siRNA). 6 h post-transfection, the siRNA containing media was removed and cells were incubated with complete media overnight. Knockdown was verified by semi-quantitative real-time PCR and by Western blot analysis. 48 h post siRNA transfection, cells were lysed with 300 μl Buffer RLT and RNA extracted (All Prep® DNA/RNA/protein mini kit, Qiagen) followed by cDNA synthesis (High Capacity RNA-to-cDNA Kit, Applied Biosystems). According to the manufacturers' manual. TaqMan® Gene Expression Master Mix Kit (Applied Biosystems) was used for the qPCR analysis according to standard protocol. Standard qPCR was done in duplicate (7500-fast real time PCR system, Applied Biosystems) with VPS35 primer and probe Hs01084427_m1 (Applied Biosystems), expression normalized with VPS35 cDNA and GAPDH primer and probe Hs02758991_g1 (Applied Biosystems). Fold difference in the expression level relative to a control sample was calculated using the comparative Ct method (Leutenegger et al., 1999) . A decrease in the mRNA level by 70% was considered acceptable for further studies.
Western blot analysis
Following siRNA treatment, cells were washed two times with PBS and harvested by centrifugation for 5 min at 1000g and lysed in lysis buffer (62.5 mM TrisHCl pH 6.8, 10% glycerol and 2% sodium dodecyl A. Ansell-Schultz et al. Molecular and Cellular Neuroscience 93 (2018) 18-26 sulphate (SDS) in distilled water). Protein concentration was determined using the DC Protein Assay Kit (BioRad Laboratories). Samples were separated on a ClearPAGE 4-20% SDS gel (C.B.S Scientific) and transferred to a 0.45 μM nitrocellulose membrane (Thermo Fisher Scientific). Blocked membranes (5% non-fat dry milk, TBS-Tween 20) were incubated with rabbit anti-VPS35 antibody (1:1000, ab97545, Abcam) or anti-Aβ antibody (1:1000, 6E10, Biolegend) followed by HRP-conjugated goat anti-rabbit antibody (Dako) at room temperature (RT). After visualization (Amersham™ ECL™, GE Health Care) membranes were analysed by ImageJ software. Equal loading was verified by reprobing the membranes with HRPconjugated anti-GAPDH antibody (1:3000, Novus Biologicals).
oAβ uptake
Overall, cells after transfection with siRNA on day 1 (as described above), were treated with oAβ-AF700 on day 2. VPS35 siRNA-treated donor cells were treated with 1 μM oAβ-AF700 in serum-free media and incubated for 3 h at 37°C. Subsequently, cells were washed three times with PBS, and incubated in complete media without oAβ for an additional 24, 48 or 72 h. Cells were then harvested by trypsinization and centrifuged for 5 min at 1500g at 4°C. Cells were re-suspended in PBS before filtration through a CellTrics 30 μm filter (Sysmex Partec GmbH). oAβ-AF700 positive cells and the oAβ-AF700 levels in the cells were measured using flow cytometry (FACSAria Flow Cytometer, BD Biosciences). The number of cells and the relative amount of oAβ in each sample was normalized to scrambled siRNA-treated control cells.
oAβ cell-to-cell transfer
To quantify oAβ transfer, recipient cells were transfected with VPS35 siRNA, 24 h after seeding (~20,000 cells/cm 2 ), as described above. The RA differentiated donor cells were seeded on top of glass coverslips coated with 1:500 laminin (~20,000 cells/cm 2 ). Donor cells were treated with 1 μM AF 700-labelled oAβ in serum-free media for 3 h and thereafter washed three times with PBS. Subsequently, the glass coverslip containing the donor cells was placed upside down on top of the recipient cells, allowing donor and recipient cells to make contacts. After 24 h, the co-culture was stopped by removing the coverslips containing donor cells, and the media was changed to fresh media containing BDNF, NRGβ1, NFG and VitD 3 for further incubation of the recipient cells. Donor cell contamination within recipient cells was carefully controlled as described previously (Sinha et al., 2018) . In brief, donor cells were labelled with BacMam 2.0 early endosomes Rab5a-RFP (Life Technologies) and RFP fluorescence was monitored in recipient cells by flow cytometry. 48 h post co-culture, the recipient cells were harvested for flow cytometry using Cell recovery solution (Corning), according to the manufacturers' protocol. Overall, donor cells were transfected with siRNA on day 1 then treated with oAβ-AF700 for 3 h followed by co-culturing with recipient cells on day 2, ending of co-culture on day 3 (24 h after co-culture was initiated) and thereafter analysed by flow cytometry on day 5 (48 h post co-culture).
The number of cells with transferred oAβ was measured in the recipient population using flow cytometry. The relative number of cells containing oAβ in each sample was normalized to scrambled siRNA-treated cells.
Immunocytochemistry
Fully differentiated SH-SY5Y cells were fixed with 4% PFA for 20 min at room temperature. Cell permeabilization was done by incubation with 0.01% Triton X-100 (Sigma Aldrich) in PBS for 30 min. Permeabilized cells were blocked with 5% fetal bovine serum for 1 h prior to addition of primary antibodies. The primary antibodies used were targeting VPS35 (1:250, ab97545, Abcam), early endosome antigen 1 (EEA1, 1:1000, Santa Cruz), or Aβ (1:250, 6E10, Biolegend).
Alexa-594 was used as a secondary antibody at a dilution of 1:250. Images were acquired with an LSM 700 Zeiss confocal microscope and micrographs were processed using ZEN lite (blue edition) software.
Statistical analysis
Data were expressed as mean ± SEM, and statistical comparison between the groups were made using two-tailed unpaired Student's ttest with Welch's correction or One-way ANOVA with Tukey multiple comparisons test using GraphPad Prism version 6.0, (GraphPad Software). P-values ≤ 0.05 were considered significant.
Results
Reduced retromer function increases oAβ accumulation
To assess the effect of reduced retromer function on the accumulation and recycling of exogenous oAβ, we transfected fully differentiated human SH-SY5Y cells with multiple siRNA sequences. Using qPCR, we identified a unique siRNA sequence that significantly reduces VPS35 gene expression compared to scrambled siRNA treatment (88.7%, Fig. 1A ). This translated into a significant reduction in VPS35 protein expression as analysed by Western blot (Fig. 1B) . The level of VPS35 reduction observed here is consistent with a previous report demonstrating that reduction of VPS35 leads to decrease retromer function (Sullivan et al., 2011) . To verify that reduction in VPS35 expression had no effect on the mechanisms involved in protein uptake, we first treated cells with 1 μM oAβ for 3 h, then immediately quantified the number of cells containing oAβ and the mean fluorescence intensity (MFI) of intracellular oAβ using flow cytometry. We observed no differences in the uptake of oAβ between VPS35 siRNA-or scrambled siRNA-treated cells, indicating that VPS35 reduction does not affect the mechanisms responsible for oAβ uptake (Fig. 1C, D) .
To assess the role of VPS35 in the recycling of oAβ, we analysed the presence of oAβ in VPS35 siRNA-treated vs. control cells (scrambled siRNA-treated) at different time points (24, 48 and 72 h post-treatment) by flow cytometry. We observed a significant increase in the number of cells containing oAβ after the VPS35 siRNA-treatment. The increased number of oAβ containing cells was present at 24, 48, as well as 72 h post oAβ treatment ( Fig. 2A-C) . This correlated with a significant increase in the amount of labelled oAβ within the cells at the same time points (24, 48 and 72 h) as measured by MFI, indicating an accumulation of oAβ within VPS35 siRNA-treated cells as a result of reduced VPS35 expression (Fig. 2 D-F) . These results imply that the retromer plays a critical role in the processing of oAβ internalised from the extracellular milieu.
oAβ treatment reduces VPS35 protein expression
To further assess whether reduced VPS35 function results in oAβ accumulation, we quantified oAβ uptake in fully differentiated recipient cells by Western blot analysis. VPS35 siRNA-treated recipient cells or control cells (scrambled siRNA) were exposed to 1 μM extracellular oAβ for 24 h. Consistent with the results above, cells with reduced retromer function showed a greater accumulation of oAβ (Fig. 3A, B) . Interestingly, when we assess the levels of VPS35 on oAβ treated recipient cells, we observed a reduction in VPS35 protein expression as a result of oAβ treatment alone (Fig. 3C, D) . Similarly, VPS35 siRNA-treated recipient cells exposed to oAβ, showed a further reduction in VPS35 expression compared to VPS35 siRNA-treated recipient cells not exposed to oAβ (Fig. 3C, D) , suggesting that oAβ treatment alone enhances the reduction of VPS35. These results are in line with previous reports suggesting a direct link between VPS35 protein expression and the presence of Aβ (Small et al., 2005) 
Reduced retromer function results in oAβ accumulation in a co-culture model system
It is now well established that oAβ and other neurodegenerative proteins spread from cell-to-cell, as summarized in several reviews, e.g. (Stopschinski and Diamond, 2017) . Thus, to further assess the role of VPS35 in a more physiological system, we used a co-culture model that allows the quantification of cell-to-cell transfer of oAβ from donor cells to recipient cells as we have previously reported (Domert et al., 2014; Nath et al., 2012) . As shown in the schematic representation (Fig. 4A) , we co-cultured donor cells containing oAβ with recipient cells pretreated with VPS35 siRNA or scrambled siRNA. After 24 h of co-culture, donor cells were removed and recipient cells were cultured for another 48 h before the number of cells containing oAβ were quantified using flow cytometry. Similar to cells that were treated with oAβ directly (Fig. 2) , recipient cells with reduced VPS35 expression also showed a significant increase in accumulation of oAβ that spread from the donor to recipient cells in a co-culture system (Fig. 4B) . Collectively, these results suggest that the major component of the retromer complex, VPS35, is a key player in the recycling of exogenous oAβ regardless of the origin of the oAβ.
oAβ co-localizes with VPS35 and early endosome markers
To assess whether oAβ co-localized with VPS35 following protein uptake, we performed confocal image analysis on VPS35 siRNA-and scrambled siRNA-treated recipient cells exposed to 1 μM extracellular oAβ for 24 h, using Aβ and VPS35 antibodies (Fig. 5A, B) . Our qualitative observations revealed a co-localization between oAβ and VPS35. Consistent with our flow cytometry and Western analysis, we observed an increase in oAβ in VPS35 siRNA-treated recipient cells compared to scrambled siRNA controls (Fig. 5A, B) . We then verified that oAβ is taken up via the endosomal pathway by co-labelling recipient cells with the early endosome antigen 1 marker (EEA1, Fig. 5C, D) . As expected, we observed a partial co-localization between Aβ and EEA1 antibodies, suggesting the involvement of the endosomal pathway in the uptake of oAβ as previously reported (Domert et al., 2014; Nath et al., 2012) . Taken together, our results suggest that decreased VPS35 expression results in the accumulation oAβ within the cell, indicating that the retromer complex plays a central role in the proper recycling of oAβ (caption on next page) A. Ansell-Schultz et al. Molecular and Cellular Neuroscience 93 (2018) 18-26 following neuronal uptake.
Discussion
In this study, we assessed the role of core retromer complex, VPS35, on the uptake and recycling of exogenous oAβ in human differentiated SH-SY5Y neuronal cells. We demonstrate that VPS35 siRNA treatment reduces retromer function and decreases the ability to clear oAβ taken up from the extracellular milieu or transferred from donor cells containing oAβ in a co-culture system. Moreover, we confirmed that oAβ is taken up via the endosomal pathway (Domert et al., 2016; Laferla et al., 2007) and is co-localized extensively with VPS35, indicating a potential interaction between oAβ protein assemblies and VPS35. Our current findings further demonstrate that VPS35 plays a critical role on the accumulation of exogenous oAβ within cells. Our results are in line with previous observations which point to VPS35 deficiency in the accumulation of Aβ in cells over expressing APP (Bhalla et al., 2012) . These findings are noteworthy given that even subtle changes in Aβ accumulation promote neurotoxicity and neurodegeneration in multiple model systems (Sullivan et al., 2011) . Fig. 2 . Reduction of VPS35 decreases oAβ processing. Flow cytometry analysis of VPS35 siRNA-or scrambled siRNA-treated cells exposed to 1 μM oAβ for 3 h shows (A-C) a significant increase in the proportion of cells containing oAβ at 24 h (n = 6), 48 h (n = 6) and72 h (n = 6) post-oAβ treatment. (D-F) Correspondingly, mean fluorescence intensity (MFI) measurements in the same flow cytometry experiments showed a significant increase in the amount of intensity of oAβ fluorescent labelling (AF700). Data expressed as mean ± SEM, p > 0.05, *p ≤ 0.05, **p ≤ 0.01 by two-tailed unpaired Student's t-tests with Welch's correction. The results which show a reduction in VPS35 protein expression following oAβ treatment alone are important given that reduction in VPS35 leads to oAβ accumulation, suggesting a predominantly inhibitory effect on the corresponding pathways responsible for oAβ processing. In line with this finding, two recent studies reported a differential downregulation of multiple genes following oAβ treatment (Kong et al., 2005; Sebollela et al., 2012) . In addition, VPS35 has been found to be essential for the endosome-to-Golgi retrieval of beta-secretase 1 (BACE-1) and loss of VPS35 function leads to increase localization of BACE1 to the endosomal compartment. The increased presence of BACE-1 concomitant with an acidic environment in endosomes is favourable for BACE1 activity, resulting in the cleavage of APP into Aβ peptides. Thus, normal function of VPS35 is vital for reducing BACE-1 levels and therefore subcellular Aβ accumulation (Wen et al., 2011) . In addition, the acidic environment in endosomes also favors Aβ aggregation (Burdick et al., 1992) . Together with our current results, this points to the retromer system as a highly attractive therapeutic target to enhance the proper recycling and clearance of oAβ (Bhalla et al., 2012; Dhungel et al., 2015; Mecozzi et al., 2014) . Indeed, Mecozzi and colleagues showed that the pharmacological compound R55, could increase the levels of VPS35 in neurons. This effect will in turn reduce the presence of BACE-1 levels within the endosomes and promote the trafficking of full length APP out of the endosome, thereby lowering the processing time of APP into neurotoxic Aβ peptides (Mecozzi et al., 2014) . Thus, enhancement of the retromer's stability and function through pharmacological intervention may be potential therapeutic strategy for the treatment of protein misfolding disorders (Mecozzi et al., 2014; Temkin et al., 2011) .
Steady-state levels of VPS35 and the retromer complex are essential for cell viability and function. In fact, both silencing and overexpression of VPS35 has been demonstrated to be detrimental to cellular health (Tsika et al., 2014) . Moreover, improper assembly of the complex itself might also lead to neuronal pathology. For instance, VPS26 has been shown to correlate with VPS35 expression (Small et al., 2005) , suggesting a potential link between VPS26 and VPS35 function. In turn, the retromer associated receptor SORLA has been shown to bind to VPS26 (Fjorback et al., 2012) . SORLA also binds to APP (Dodson et al., 2006) and its deficiency has been associated with increased Aβ production (Offe et al., 2006; Rogaeva et al., 2007 ). These studies demonstrate that the retromer complex as a whole, plays a major role in Aβ processing. Interestingly, VPS35 dysfunction has also been linked to impaired autophagy through the formation and function of the autophagosomes (Zavodszky et al., 2014) , this is interesting since autophagy dysfunction has emerged as an important mechanism for neurons to clear neurotoxic aggregates in neurodegenerative disorders (Nilsson et al., 2015; Nixon, 2013) . The lack of maturation of autophagy-related vesicular structures identified in AD (Nixon, 2006) points to the lack of Aβ processing and as such, an increase in the intracellular Aβ. The accumulation of Aβ in the multivesicular body (MVB) has also been identified to decrease proteasomal activity (Almeida et al., 2006) . Hence, reduced function of the retromer system could potentially affect multiple cellular mechanisms responsible for the clearance of protein aggregates resulting in an overall accumulation of Aβ within the cell.
Conclusion
Previous studies have indicated that the retromer system plays an important role in synaptic remodelling and plasticity by mediating the normal delivery and sorting of multiple proteins to their respective compartments. Thus, it is not surprising that retromer dysfunction has been linked to several neurodegenerative diseases, including AD. In this study, we provide compelling evidence that reduced retromer function decreases the ability for neurons to transport and clear neurotoxic oAβ resulting in the accumulation of protein aggregates. Therefore, enhancing retromer function may be a potential therapeutic strategy to slow down the pathophysiology associated with the progression of AD.
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